IC
BMY.RT

Ikarian Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Ikarian Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-644,021
Closed -$444K – 347
2020
Q4 		$444K Sell
644,021
-1,155,979
-64% -$2.46M 0.02% 194
2020
Q3 		$4.05M Buy
1,800,000
+700,000
+64% +$2M 0.29% 78
2020
Q2 		$3.94M Buy
1,100,000
+150,000
+16% +$541K 0.31% 74
2020
Q1 		$3.61M Buy
+950,000
New +$3.13M 0.27% 75

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Ikarian Capital's BMY.RT Position: Q1 2021 in Review

Ikarian Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 644,021 shares — an estimated $444K sold.

Ikarian Capital first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $4.05M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Ikarian Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Ikarian Capital sold 644,021 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $444K.
  • Ikarian Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Ikarian Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4.05M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.